top of page
Resources


The Launch Gap
Why the Technology Layer Is Where Pre-Commercial Biotechs Fall Behind More than half of pharma launches underperform expectations, and fewer than 20 percent recover after the first six months. For first-time launchers, the gap is rarely the science. It is the commercial technology layer that nobody plans for until launch pressure exposes it. This white paper defines the seven domains of commercial IT readiness, explains why they get deferred, and provides a practical 24-month


The Strategic Advantage of Fractional CIOs for Pre-Commercial Biotech Companies: Accelerating Success in Phase 3 and Product Launch
Executive Summary In the high-stakes world of biotechnology, pre-commercial companies in Phase 3 clinical trials face a critical juncture. As they prepare for their first product launch in the US market, the need for agile, cost-effective, and specialized IT leadership has never been more crucial. This white paper explores why Fractional Chief Information Officers (CIOs) are emerging as the strategic choice for biotech firms navigating this pivotal phase, offering a compellin


Operationalize DW & BI at Pre-Commercial Oncology Biotech
In the highly competitive biopharmaceutical industry, delivering groundbreaking therapies to patients requires more than scientific...


Achieving Efficiency Under Pressure: Streamlining an IT Budget Without Sacrificing Performance
In today’s fast-paced business environment, IT departments are increasingly expected to do more with less. For one large organization,...


Integrating Digital Factory shadow IT into IT department of a global biotechnology company
A Smooth Transition to Unified Excellence In the world of biotechnology, staying at the cutting edge of digital innovation is essential...


Omnichannel Strategy and Execution at a Pharma Eyecare & Medical Aesthetics Company
A specialty eyecare pharmaceutical company embarked on a pivotal journey to expand its reach and redefine patient access. Having...


Commercial IT enablement for a Global Oncology Biotech
The company faced a monumental challenge: scaling its operations to support the US sales expansion of very rare orphan drugs , while...


Building a Future-Ready IT Foundation for Emcitate® EU launch at Egetis
Egetis Therapeutics is a pioneering biopharmaceutical company dedicated to addressing the profound unmet needs of patients with...


Bexafemme Launch at Scynexis
SCYNEXIS faced an extraordinary challenge: launching Brexafemme , a groundbreaking prescription oral treatment designed to eliminate the...


Nefecon Launch at Calliditas
Callidatas US faced a formidable task: launching Nefecon, an orphan drug designed to treat the rare disease IgA Nephropathy (IgAN), in...


Enabling IT for Hutchmed's Future Launches
Hutchmed, a global biopharmaceutical company, is at the forefront of advancing innovative therapies for cancer and immunological...
bottom of page
